Jesús Venegas-Ramìrez

Dr. Jesús Venegas-Ramìrez

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
JVJesús Venegas-Ramìrez
Jesús Venegas-Ramìrez
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
CPClaudia S. Palomares
Claudia S. Palomares
JDJanet Diaz-Martinez
Janet Diaz-Martinez
RGRosa M González
Rosa M González
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Background and Objectives: Arteriovenous fistulas (AVFs) are the preferred vascular access for hemodialysis due to their impact on patient outcomes, including survival, infection rates, and overall quality of life. Despite strong recommendations favoring AVF, gaps in AVF utilization remain, influenced by clinical, demographic, and systemic factors. This study is the first to analyze survival outcomes associated with different dialysis vascular access types, adjusting for key clinical, demographic variables, and other comorbidities over extended periods. Materials and Methods: This ambispective cohort study followed 428 hemodialysis patients over seven years. Patients were categorized based on their access type: AVF (n = 189), tunneled central venous catheter (CVC) (n = 178), and non-tunneled CVC (n = 61). Kaplan–Meier survival analysis was used to estimate survival curves, and Cox proportional hazards regression adjusted for potential confounders, including age, diabetes, and hypertension. Results: The 2-year survival rates were as follows: AVF 94.1%, tunneled CVC 70.0%, and non-tunneled CVC 36.6%. The 7-year survival rates were as follows: AVF 65.5%, tunneled CVC 26.4%, and non-tunneled CVC 11.0%. Compared to AVF, tunneled CVC use was associated with a 2.8-fold increased risk of mortality (adjusted hazard ratio [AdHR] 2.8, 95% CI 2.0–4.1), while non-tunneled CVC increased the risk 5-fold (AdHR 5.0, 95% CI 3.3–7.6). Notably, older adults, women, and diabetic patients were disproportionately represented in the groups with tunneled and non-tunneled catheters. Conclusions: Adjusted survival analyses highlight the significantly lower survival rates associated with CVC use compared to AVF. Non-tunneled catheters are generally not used for prolonged periods, and this cohort provides evidence of their prognosis for long-term use. These findings reinforce the need to prioritize AVF placement whenever feasible, reinforcing health education on this topic, to improve long-term outcomes for hemodialysis patients.

1 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YAYalila Valeria Navarrete Anaya
Yalila Valeria Navarrete Anaya
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
JDJanet Diaz-Martinez
Janet Diaz-Martinez
DDDelgado-Enciso Delgado-Enciso
Delgado-Enciso Delgado-Enciso
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
Background/Objectives: Erectile dysfunction (ED) is a prevalent and multifactorial condition influenced by psychological and sleep-related factors. This study aimed to evaluate the independent and combined associations of insomnia and benzodiazepine use with the risk of ED. Methods: An analytical cross-sectional study was conducted in adult men with and without ED. Logistic regression was used to estimate crude and adjusted odds ratios (ORs). Effect modification was assessed through stratified analyses. Additionally, an in silico analysis of 17 active compounds was performed using SwissADME and Molinspiration to explore physicochemical properties. Results: Insomnia (adjusted OR 2.05; 95% CI 1.13–3.74; p = 0.019) and benzodiazepine use (adjusted OR 2.14; 95% CI 1.10–4.15; p = 0.025) were each independently associated with ED. In contrast, antidepressant use was not significantly associated with ED in the sample analyzed. Participants with both insomnia and benzodiazepine use had a markedly higher risk (adjusted OR 3.96; 95% CI 1.51–10.40; p = 0.005). The joint association of insomnia and benzodiazepine use was consistent with the combined effect expected from their individual associations. The in silico analysis showed an overlapping profile, suggesting benzodiazepine properties may underline their link to ED, supporting the results of the cross-sectional study. Conclusions: Both insomnia and benzodiazepine use independently increased the odds of ED. Their co-occurrence was linked to a substantially higher likelihood of ED, highlighting the clinical importance of assessing both conditions concurrently in patients with sexual dysfunction.

25 May 2025 in Toxics
Verified
Journal Article
Open access
PDF file
ACArlette A Camacho-delaCruz
Arlette A Camacho-delaCruz
OMOliver Mendoza-Cano
Oliver Mendoza-Cano
XTXóchitl Trujillo
Xóchitl Trujillo
MHMiguel Huerta
Miguel Huerta
MRMonica Rios-Silva
Monica Rios-Silva
Efrén Murillo-ZamoraEfrén Murillo-Zamora
Efrén Murillo-Zamora
Children constitute a population at risk from environmental exposure to trace elements. This study aimed to evaluate correlations between urinary and blood levels of multiple elements in school-aged children (5–12 years), assessing whether urine, a less invasive matrix, could complement or replace blood sampling. A pilot biomonitoring study was conducted, and 91 children provided urine and venous blood samples in which the levels of 17 contaminants (Al, As, Ba, Cs, Co, Cu, I, Pb, Li, Mn, Mo, Ni, Se, Sr, Te, Ti, and Zn) were assessed. Spearman correlation coefficients (rho) and 95% confidence intervals (CI) were computed. Urinary and blood levels of arsenic (rho = 0.23, 95% CI 0.01–0.44), lead (rho = 0.43, 95% CI 0.24–0.61), and strontium (rho = 0.22, 95% CI 0.03–0.40) showed significant correlations. These findings suggest that urine sampling could serve as a practical alternative to blood collection for monitoring specific trace elements like lead in pediatric populations, particularly in large-scale studies where participant compliance is critical. However, modest correlations for other elements highlight the need for element-specific validation before adopting urine as a universal biomonitoring matrix. Future research should explore the pharmacokinetic and exposure-related factors driving these relationships to optimize non-invasive surveillance strategies for children’s environmental health.

24 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
HGHossana S. Garcia-Garcia
Hossana S. Garcia-Garcia
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
JVJesús Venegas-Ramìrez
Jesús Venegas-Ramìrez
CBCarlos D. Barajas-Mejía
Carlos D. Barajas-Mejía
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Background/Objectives: Metastatic prostate cancer remains a major clinical challenge, with limited therapeutic options. Doxycycline, a tetracycline antibiotic with anti-inflammatory properties, has shown potential as an adjunctive therapy. This study aimed to evaluate its efficacy in reducing prostate-specific antigen (PSA) levels and improving quality of life in patients receiving standard treatment for metastatic prostate cancer. Methods: This phase II, double-blind, randomized controlled trial included 45 participants (aged 57–81 years) assigned to doxycycline (100 mg daily) or a placebo for six months. The primary outcome was the percentage change in PSA levels at 3 and 6 months. Secondary outcomes included quality of life (EQ-5D-5L), cognitive function (Mini-Mental State Examination), and glucose levels. Additionally, a structure–activity relationship (SAR) analysis was performed through an extensive bibliographic review to identify pharmacophores responsible for doxycycline’s biological activity, particularly its tetracyclic core. The SAR analysis included tetracyclines and derivatives, androgen-targeting agents, and other pharmacologically relevant molecules used in prostate cancer therapy. Statistical analysis was conducted using multivariate logistic regression. Results: At six months, the doxycycline group showed a median PSA reduction of 60% compared to 10% in the placebo group (p = 0.043). A ≥50% reduction in PSA levels was observed in 71.4% of patients receiving doxycycline versus 20.8% in the placebo group (p = 0.001), with an adjusted relative risk of 10.309 (95% CI: 2.359–45.055, p = 0.002). Quality of life improved, with 7.1% of doxycycline-treated patients reporting poor quality of life compared to 42.9% in the placebo group (p = 0.028). A slight improvement in cognitive function was also noted (p = 0.037). SAR analysis suggested that the tetracyclic ring of doxycycline may play a crucial role in its observed biological effects. Conclusions: Doxycycline demonstrates potential as an adjunctive therapy in metastatic prostate cancer by reducing PSA levels and improving quality of life. The SAR analysis supports the hypothesis that its tetracyclic structure may be responsible for its therapeutic effects. Further large-scale trials are warranted to confirm these findings.

22 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
KPKayim Pineda-Urbina
Kayim Pineda-Urbina
JDJanet Diaz-Martinez
Janet Diaz-Martinez
CHCARLOS HERNANDEZ
CARLOS HERNANDEZ
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Background/Objectives: Genitourinary cancers represent a major and growing source of cancer burden worldwide; however, important disparities persist across the Americas. This study aimed to evaluate the incidence, mortality, and disability burden of prostate, testicular, bladder, and kidney cancers across 38 countries and territories using Global Burden of Disease (GBD) 2023 estimates, with emphasis on temporal trends and sociodemographic inequalities. Methods: A descriptive ecological study was conducted using Global Burden of Disease (GBD) 2023 estimates. Age-standardized incidence, mortality, and disability-adjusted life year (DALY) rates per 100,000 population were analyzed for prostate, bladder, kidney, and testicular cancers. Burden estimates were obtained from GBD 2023 data, and temporal trend analyses were conducted using age-standardized rates from 2000–2023. Temporal trends were assessed using weighted log-linear regression to estimate annual percentage changes (APCs) based on age-standardized rates from 2000–2023. Results: In 2023, prostate cancer accounted for the greatest genitourinary cancer burden across the Americas, with high incidence concentrated in high-income North America, whereas mortality and DALY rates were disproportionately elevated in Latin America and the Caribbean. Across all cancer types, high-SDI regions consistently exhibited higher incidence but more favorable mortality and disability profiles. Testicular cancer incidence increased across all SDI quintiles, although mortality reductions were mainly observed in high-SDI settings. Bladder and kidney cancers demonstrated similar epidemiological patterns, with declining mortality trends in high-income regions but persistent or increasing burden in lower-SDI countries. Mortality-to-incidence disparities remained substantial across Latin America and the Caribbean, which may reflect differences in healthcare resources, early detection, treatment availability, or other contextual factors not directly captured in the GBD database. National extremes included Bermuda prostate ASIR 170.63 and Dominica DALYs 1423.30 per 100,000. Conclusions: The burden of genitourinary cancers across the Americas remains strongly associated with socioeconomic inequalities. Although higher-resource settings have achieved important reductions in mortality and disability, these gains have not been equitably distributed across the region. Strengthening health system capacity, improving early diagnosis, and ensuring equitable access to evidence-based cancer care are essential to reduce avoidable mortality and improve long-term outcomes throughout the Americas.

26 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YAYalila Valeria Navarrete Anaya
Yalila Valeria Navarrete Anaya
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
JDJanet Diaz-Martinez
Janet Diaz-Martinez
DDDelgado-Enciso Delgado-Enciso
Delgado-Enciso Delgado-Enciso
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
Background/Objectives: Erectile dysfunction (ED) is a prevalent and multifactorial condition influenced by psychological and sleep-related factors. This study aimed to evaluate the independent and combined contributions of insomnia and antidepressant use to the risk of ED. Methods: A case-control study was conducted including adult men with and without ED. Logistic regression was used to estimate crude and adjusted odds ratios (ORs). A stepwise multivariable model (entry p < 0.5, exit p < 0.1) identified significant predictors. Effect modification was explored through stratified analyses and additive interaction indices: relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S). Results: Insomnia (adjusted OR 1.98; 95% CI 1.09–3.60; p = 0.026) and antidepressant use (adjusted OR 2.04; 95% CI 1.12–3.72; p = 0.021) were each independently associated with ED. Participants with both exposures had a markedly higher risk (adjusted OR 3.94; 95% CI 1.67–9.26; p = 0.002). However, interaction indices (RERI ≈ 0.03; S ≈ 1.01) suggested no statistically significant synergistic interaction. The combined effect approximated the sum of individual effects, indicating an additive rather than synergistic relationship. Conclusions: Both insomnia and antidepressant use independently increased the odds of ED. Although no significant statistical interaction was found, their co-occurrence was associated with a substantially higher risk, underscoring the clinical importance of evaluating and addressing both factors in the management of ED.